<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03591068</url>
  </required_header>
  <id_info>
    <org_study_id>OPN-FLU-NP-3104</org_study_id>
    <nct_id>NCT03591068</nct_id>
  </id_info>
  <brief_title>Efficacy &amp; Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video</brief_title>
  <official_title>A 24-Week Open-Label Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optinose US Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Optinose US Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 24-week, open-label, multi-center study designed to assess the efficacy and safety&#xD;
      of OPN-375 186 μg twice a day in subjects with nasal polyps using Nasoendoscopic video. The&#xD;
      total planned number of subjects is approximately 10, with each subject receiving OPN-375 186&#xD;
      μg twice a day.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the efficacy and safety of OPN-375 186 μg&#xD;
      twice a day in adults with Bilateral Nasal Polyps using Nasoendoscopic video. The secondary&#xD;
      objectives of this study are to evaluate the safety of OPN-375 via adverse event reports,&#xD;
      vital signs, and nasal examination. In addition, to measure any change in subject symptoms&#xD;
      and functioning from Baseline to 12 and 24 weeks during the study, using the Sinonasal&#xD;
      Outcome Test -22 (SNOT-22), Patient's Global Impression of Change (PGIC), and measurement of&#xD;
      nasal polyps by independent, blinded reader, and any changes throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 7, 2018</start_date>
  <completion_date type="Actual">February 22, 2019</completion_date>
  <primary_completion_date type="Actual">February 22, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Visit 1 at End of Study in Bilateral Nasal Polyp Grade Using Endoscopic Video</measure>
    <time_frame>Week 24</time_frame>
    <description>: Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps&#xD;
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate&#xD;
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate&#xD;
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment for Safety by Recording Adverse Events and Adverse Events of Special Interests</measure>
    <time_frame>24 Weeks, up to 30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment for Safety Through Nasal Examination</measure>
    <time_frame>24 Weeks, up to 30 days after last dose</time_frame>
    <description>Assessed in nasal examination worksheet which includes recording the presence of any epistaxis, septal erosion/perforation, ulceration/erosion of area other than septum. If present, the nostril location is also recorded, along with severity, and if there is any relation to an injury or trauma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment for Safety From Recording Vital Sign - Blood Pressure</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
    <description>Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment for Safety From Recording Vital Sign - Pulse</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
    <description>measure pulse in beats per minute (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment for Safety From the Collection of Information for Concomitant Medications Usage</measure>
    <time_frame>24 Weeks, up to 30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Polyp Grading Score (Sum of Scores From Both Nasal Cavities)</measure>
    <time_frame>Week 24</time_frame>
    <description>Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps&#xD;
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate&#xD;
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate&#xD;
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a Change of Greater Than or Equal to 1 Point in Bilateral Polyp Grade</measure>
    <time_frame>Week 24</time_frame>
    <description>Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps&#xD;
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate&#xD;
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate&#xD;
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a Polyp Grade of 0 on at Least One Side of the Nose at Each Visit</measure>
    <time_frame>Week 24</time_frame>
    <description>Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps&#xD;
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate&#xD;
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate&#xD;
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sinonasal Outcome Test 22 (SNOT-22) Total Score</measure>
    <time_frame>Week 24</time_frame>
    <description>SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst.&#xD;
0: No problem&#xD;
Very mild problem&#xD;
Mild or slight problem&#xD;
Moderate problem&#xD;
Severe problem&#xD;
Problem as bad as can be</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sniffin' Sticks N-butanol Test</measure>
    <time_frame>Week 24</time_frame>
    <description>The Sniffin' Sticks n-butanol (Extended test) are used to investigate human olfactory performance by use of odor pens. the Extended Test consists of 3 different subtests: Threshold, Discrimination and Identification. the Threshold test is used to ascertain the patient's olfactory threshold. the Discrimination test requires the patient to differentiate smells. The Identification test requires the patient to identify everyday smells by means of a card with different choices. The result of this test is expressed as the sum of the results of the 3 subtests, the so called TDI score (threshold, discrimination, identification). A score of more than 30 rates as normal, a score of 30 or less indicates hyposmia and a score of 15 and below point to functional anosmia in form of complete loss of the sense of smell or an extremely weakened smell ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a PGIC Score of Minimally/Much/Very Much Improved</measure>
    <time_frame>Week 24</time_frame>
    <description>The Patient Global Impression of Change (PGIC), is a questionnaire where the patient rates the change in their symptoms. Score range is from 1 (very much improved) to 7 (very much worse)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Nasal Polyposis</condition>
  <arm_group>
    <arm_group_label>OPN-375 186 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone Propionate</intervention_name>
    <description>OPN-375 186 μg BID, Delivered via exhalation delivery system</description>
    <arm_group_label>OPN-375 186 mcg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or women aged 18 years and older at Visit 1 (Baseline/Day1)&#xD;
&#xD;
          2. Women of child bearing potential must be abstinent, or if sexually active,&#xD;
&#xD;
               1. be practicing an effective method of birth control (e.g., prescription oral&#xD;
                  contraceptives, contraceptive injections, contraceptive patch, intrauterine&#xD;
                  device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with&#xD;
                  spermicidal foam, cream, or gel], or male partner sterilization) before entry and&#xD;
                  throughout the study, or&#xD;
&#xD;
               2. be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal&#xD;
                  ligation, or otherwise be incapable of pregnancy), or&#xD;
&#xD;
               3. be postmenopausal (amenorrhea for at least 1 year).&#xD;
&#xD;
          3. Women of child-bearing potential must have a negative urine pregnancy test at Visit 1&#xD;
             (Day 1/Baseline)&#xD;
&#xD;
          4. Must have bilateral nasal polyposis with a grade of 2 or 3 in at least one side of the&#xD;
             nasal cavity as determined by a nasal polyp grading scale score measured by&#xD;
             nasoendoscopy at Visit 1 (Day 1/Baseline)&#xD;
&#xD;
          5. Must have a SNOT-22 score of ≥20 at Visit 1(Baseline/Day 1)&#xD;
&#xD;
          6. Must have been on an adequate dose of an intranasal corticosteroid (e.g. fluticasone&#xD;
             propionate, fluticasone furoate, mometasone, triamcinolone, ciclosenide, budesonide,&#xD;
             budesonide respules, beclomethasone) for at least 1 month, in the previous 3 months&#xD;
             prior to Visit 1 (Day 1/Baseline)&#xD;
&#xD;
          7. Subjects with comorbid asthma or chronic obstructive pulmonary disease (COPD) must be&#xD;
             stable with no exacerbations (e.g., no emergency room visits, hospitalization, or oral&#xD;
             or parenteral steroid use) within the 3 months before the screening visit. Inhaled&#xD;
             corticosteroid use must be limited to stable doses of no more than 1,000 μg/day of&#xD;
             beclomethasone (or equivalent) for at least 3 months before screening with plans to&#xD;
             continue use throughout the study&#xD;
&#xD;
          8. Must be able to cease treatment with oral steroids, intranasal steroids, inhaled&#xD;
             corticosteroids (except permitted doses listed above for asthma and COPD) at Visit 1&#xD;
             (Day 1/Baseline)&#xD;
&#xD;
          9. Must demonstrate correct use of the demo EDS&#xD;
&#xD;
         10. Ability to read and speak English&#xD;
&#xD;
         11. Must be capable, in the opinion of the investigator, of providing informed consent to&#xD;
             participate in the study. Subjects must sign an informed consent document indicating&#xD;
             that they understand the purpose of and procedures required for the study and are&#xD;
             willing to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant or lactating&#xD;
&#xD;
          2. Inability to have each nasal cavity examined for any reason, including nasal septum&#xD;
             deviation&#xD;
&#xD;
          3. Have used XHANCE™ (fluticasone propionate) nasal spray within the past 2 months&#xD;
&#xD;
          4. Nasal septum perforation&#xD;
&#xD;
          5. Has had more than 1 episode of epistaxis with frank bleeding in the month before Visit&#xD;
             1 (Day 1/Baseline)&#xD;
&#xD;
          6. Have evidence of significant mucosal injury or ulceration (e.g. exposed cartilage) on&#xD;
             Visit 1 (Day 1/Baseline) nasal examination/nasoendoscopy&#xD;
&#xD;
          7. History of sinus or nasal surgery within 3 months before Visit 1 (Day 1/Baseline). If&#xD;
             &gt;3 months subject should be fully recovered from surgery&#xD;
&#xD;
          8. Current, ongoing rhinitis medicamentosa (rebound rhinitis)&#xD;
&#xD;
          9. Have significant oral structural abnormalities, e.g., a cleft palate&#xD;
&#xD;
         10. Diagnosis of cystic fibrosis&#xD;
&#xD;
         11. History of Churg-Strauss syndrome or dyskinetic ciliary syndromes&#xD;
&#xD;
         12. Purulent nasal infection, acute sinusitis, or upper respiratory tract infection within&#xD;
             2 weeks before Visit 1 (Day 1/Baseline). Potential subjects presenting with any of&#xD;
             these infections may be rescreened 4 weeks after symptom resolution&#xD;
&#xD;
         13. Planned sinonasal surgery during the period of the study&#xD;
&#xD;
         14. Allergy, hypersensitivity, or contraindication to corticosteroids, steroids, or to any&#xD;
             excipients in OPN-375&#xD;
&#xD;
         15. Exposure to any glucocorticoid treatment with potential for systemic effects (e.g.,&#xD;
             oral, parenteral, intra-articular, or epidural steroids, high dose topical steroids)&#xD;
             within 1 month before Visit 1 (Day 1/Baseline); except as noted in inclusion criteria&#xD;
             for subjects with comorbid asthma or COPD&#xD;
&#xD;
         16. Have nasal candidiasis at Visit 1 (Day 1/Baseline)&#xD;
&#xD;
         17. History or current diagnosis of any form of glaucoma, ocular hypertension, or&#xD;
             intraocular pressure elevation on any form of steroid therapy&#xD;
&#xD;
         18. History or current diagnosis of the presence (in either eye) of a sub-capsular&#xD;
             cataract&#xD;
&#xD;
         19. Any serious or unstable concurrent disease, psychiatric disorder, or any significant&#xD;
             condition that, in the opinion of the investigator could confound the results of the&#xD;
             study or could interfere with the subject's participation or compliance in the study&#xD;
&#xD;
         20. Recent (within 1 year of Visit 1 (Day 1/Baseline)) history of drug or alcohol abuse,&#xD;
             or dependence that, in the opinion of the investigator could interfere with the&#xD;
             subject's participation or compliance in the study&#xD;
&#xD;
         21. Have participated in an investigational drug clinical trial within 30 days of Visit 1&#xD;
             (Day 1/Baseline)&#xD;
&#xD;
         22. Employees of the investigator or study center, with direct involvement in the proposed&#xD;
             study or other studies under the direction of that investigator or study center, as&#xD;
             well as family members of the employees or the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Carothers</last_name>
    <role>Study Director</role>
    <affiliation>Optinose US Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Messina</last_name>
    <role>Study Chair</role>
    <affiliation>Optinose US Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado SOM, Department of Otolaryngology</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston, McGovern Medical School, Dept. of Otolaryngology, Head and Neck Surgery</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <results_first_submitted>February 21, 2020</results_first_submitted>
  <results_first_submitted_qc>July 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2020</results_first_posted>
  <last_update_submitted>July 31, 2020</last_update_submitted>
  <last_update_submitted_qc>July 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Xhance</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT03591068/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT03591068/Prot_SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OPN-375 186 mcg BID</title>
          <description>Fluticasone Propionate: OPN-375 186 μg BID, Delivered via exhalation delivery system</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OPN-375 186 mcg BID</title>
          <description>Fluticasone Propionate: OPN-375 186 μg BID, Delivered via exhalation delivery system</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Polyp Grading Score (sum of scores from both nasal cavities)</title>
          <description>Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy.&#xD;
0: No polyps&#xD;
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate&#xD;
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate&#xD;
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.1" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sinonasal Outcome Test 22 (SNOT-22) Total Score</title>
          <description>SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst.&#xD;
0: No problem&#xD;
Very mild problem&#xD;
Mild or slight problem&#xD;
Moderate problem&#xD;
Severe problem&#xD;
Problem as bad as can be</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.8" lower_limit="26" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sniffin' Sticks n-butanol tests</title>
          <description>Consists of 3 different subtests: Threshold, Discrimination and Identification. Threshold test is used to analyze the olfactory threshold. Discrimination test requires the patient to differentiate smells. Identification test requires the patient to identify everyday smells through a card with various choices. Result of this test is expressed as sum of results of 3 subtests (TDI score). A score of &gt; 30 rates as normal, a score of &lt;=30 indicates hyposmia and a score of &lt;=15 point to functional anosmia in form of complete loss of the sense of smell or an extremely weakened smell ability.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.8" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Visit 1 at End of Study in Bilateral Nasal Polyp Grade Using Endoscopic Video</title>
        <description>: Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps&#xD;
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate&#xD;
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate&#xD;
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OPN-375 186 mcg BID</title>
            <description>Fluticasone Propionate: OPN-375 186 μg BID, Delivered via exhalation delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Visit 1 at End of Study in Bilateral Nasal Polyp Grade Using Endoscopic Video</title>
          <description>: Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps&#xD;
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate&#xD;
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate&#xD;
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment for Safety by Recording Adverse Events and Adverse Events of Special Interests</title>
        <time_frame>24 Weeks, up to 30 days after last dose</time_frame>
        <population>No TEAE was experienced by more than a single subject</population>
        <group_list>
          <group group_id="O1">
            <title>OPN-375 186 mcg BID</title>
            <description>Fluticasone Propionate: OPN-375 186 μg BID, Delivered via exhalation delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment for Safety by Recording Adverse Events and Adverse Events of Special Interests</title>
          <population>No TEAE was experienced by more than a single subject</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fungal skin infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lacrimation increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal discharge discolouration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinusitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tension headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper respiratory tract infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasomotor rhinitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment for Safety Through Nasal Examination</title>
        <description>Assessed in nasal examination worksheet which includes recording the presence of any epistaxis, septal erosion/perforation, ulceration/erosion of area other than septum. If present, the nostril location is also recorded, along with severity, and if there is any relation to an injury or trauma</description>
        <time_frame>24 Weeks, up to 30 days after last dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OPN-375 186 mcg BID</title>
            <description>Fluticasone Propionate: OPN-375 186 μg BID, Delivered via exhalation delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment for Safety Through Nasal Examination</title>
          <description>Assessed in nasal examination worksheet which includes recording the presence of any epistaxis, septal erosion/perforation, ulceration/erosion of area other than septum. If present, the nostril location is also recorded, along with severity, and if there is any relation to an injury or trauma</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Epistaxis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Septal erosion/perforation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulceration/erosion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment for Safety From Recording Vital Sign - Blood Pressure</title>
        <description>Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)</description>
        <time_frame>Baseline, Week 12, Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OPN-375 186 mcg BID - Systolic BP</title>
            <description>Fluticasone Propionate: OPN-375 186 μg BID, Delivered via exhalation delivery system</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 186 mcg BID - Diastolic BP</title>
            <description>Fluticasone Propionate: OPN-375 186 μg BID, Delivered via exhalation delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment for Safety From Recording Vital Sign - Blood Pressure</title>
          <description>Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.1" spread="14.3"/>
                    <measurement group_id="O2" value="83.3" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.4" spread="19.6"/>
                    <measurement group_id="O2" value="82.0" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.9" spread="18.8"/>
                    <measurement group_id="O2" value="81.4" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment for Safety From Recording Vital Sign - Pulse</title>
        <description>measure pulse in beats per minute (bpm)</description>
        <time_frame>Baseline, Week 12, Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OPN-375 186 mcg BID</title>
            <description>Fluticasone Propionate: OPN-375 186 μg BID, Delivered via exhalation delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment for Safety From Recording Vital Sign - Pulse</title>
          <description>measure pulse in beats per minute (bpm)</description>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.5" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment for Safety From the Collection of Information for Concomitant Medications Usage</title>
        <time_frame>24 Weeks, up to 30 days after last dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OPN-375 186 mcg BID</title>
            <description>Fluticasone Propionate: OPN-375 186 μg BID, Delivered via exhalation delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment for Safety From the Collection of Information for Concomitant Medications Usage</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACE Inhibitor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiotensin II Receptor Antagonist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antianginal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anticoagulant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antihistamine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antifungal Cream</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ascorbic Acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Blocking Agent, selective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta2 Adrenergic Agonist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biguanide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium Channel Blocker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CNS Muscle Relaxant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diuretic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Electolytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HMG CoA Reductase Inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inhaled Corticosteroid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inhaled Corticosteroid/Long-acting beta-agonist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukotriene Receptor Antagonists</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multivitamin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nitrate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-steroidal anti-inflammatory drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nuclear factor erythroid-2-related factor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Selective serotonin reuptake inhibitor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Synthetic nucleoside analogue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other analgesics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other antiinflammatorys</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Topical antibiotics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proton pump inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thyroid Hormone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Polyp Grading Score (Sum of Scores From Both Nasal Cavities)</title>
        <description>Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps&#xD;
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate&#xD;
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate&#xD;
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OPN-375 186 mcg BID</title>
            <description>Fluticasone Propionate: OPN-375 186 μg BID, Delivered via exhalation delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Total Polyp Grading Score (Sum of Scores From Both Nasal Cavities)</title>
          <description>Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps&#xD;
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate&#xD;
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate&#xD;
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a Change of Greater Than or Equal to 1 Point in Bilateral Polyp Grade</title>
        <description>Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps&#xD;
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate&#xD;
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate&#xD;
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OPN-375 186 mcg BID</title>
            <description>Fluticasone Propionate: OPN-375 186 μg BID, Delivered via exhalation delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Change of Greater Than or Equal to 1 Point in Bilateral Polyp Grade</title>
          <description>Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps&#xD;
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate&#xD;
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate&#xD;
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a Polyp Grade of 0 on at Least One Side of the Nose at Each Visit</title>
        <description>Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps&#xD;
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate&#xD;
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate&#xD;
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OPN-375 186 mcg BID</title>
            <description>Fluticasone Propionate: OPN-375 186 μg BID, Delivered via exhalation delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Polyp Grade of 0 on at Least One Side of the Nose at Each Visit</title>
          <description>Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps&#xD;
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate&#xD;
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate&#xD;
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sinonasal Outcome Test 22 (SNOT-22) Total Score</title>
        <description>SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst.&#xD;
0: No problem&#xD;
Very mild problem&#xD;
Mild or slight problem&#xD;
Moderate problem&#xD;
Severe problem&#xD;
Problem as bad as can be</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OPN-375 186 mcg BID</title>
            <description>Fluticasone Propionate: OPN-375 186 μg BID, Delivered via exhalation delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Sinonasal Outcome Test 22 (SNOT-22) Total Score</title>
          <description>SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst.&#xD;
0: No problem&#xD;
Very mild problem&#xD;
Mild or slight problem&#xD;
Moderate problem&#xD;
Severe problem&#xD;
Problem as bad as can be</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sniffin' Sticks N-butanol Test</title>
        <description>The Sniffin' Sticks n-butanol (Extended test) are used to investigate human olfactory performance by use of odor pens. the Extended Test consists of 3 different subtests: Threshold, Discrimination and Identification. the Threshold test is used to ascertain the patient's olfactory threshold. the Discrimination test requires the patient to differentiate smells. The Identification test requires the patient to identify everyday smells by means of a card with different choices. The result of this test is expressed as the sum of the results of the 3 subtests, the so called TDI score (threshold, discrimination, identification). A score of more than 30 rates as normal, a score of 30 or less indicates hyposmia and a score of 15 and below point to functional anosmia in form of complete loss of the sense of smell or an extremely weakened smell ability.</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OPN-375 186 mcg BID</title>
            <description>Fluticasone Propionate: OPN-375 186 μg BID, Delivered via exhalation delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Sniffin' Sticks N-butanol Test</title>
          <description>The Sniffin' Sticks n-butanol (Extended test) are used to investigate human olfactory performance by use of odor pens. the Extended Test consists of 3 different subtests: Threshold, Discrimination and Identification. the Threshold test is used to ascertain the patient's olfactory threshold. the Discrimination test requires the patient to differentiate smells. The Identification test requires the patient to identify everyday smells by means of a card with different choices. The result of this test is expressed as the sum of the results of the 3 subtests, the so called TDI score (threshold, discrimination, identification). A score of more than 30 rates as normal, a score of 30 or less indicates hyposmia and a score of 15 and below point to functional anosmia in form of complete loss of the sense of smell or an extremely weakened smell ability.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a PGIC Score of Minimally/Much/Very Much Improved</title>
        <description>The Patient Global Impression of Change (PGIC), is a questionnaire where the patient rates the change in their symptoms. Score range is from 1 (very much improved) to 7 (very much worse)</description>
        <time_frame>Week 24</time_frame>
        <population>Number of participants who responded that they had some degree of improvement in their symptoms (minimally/much/very much improved)</population>
        <group_list>
          <group group_id="O1">
            <title>OPN-375 186 mcg BID</title>
            <description>Fluticasone Propionate: OPN-375 186 μg BID, Delivered via exhalation delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a PGIC Score of Minimally/Much/Very Much Improved</title>
          <description>The Patient Global Impression of Change (PGIC), is a questionnaire where the patient rates the change in their symptoms. Score range is from 1 (very much improved) to 7 (very much worse)</description>
          <population>Number of participants who responded that they had some degree of improvement in their symptoms (minimally/much/very much improved)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks, and up to 30 days after the last dose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>OPN-375 186 mcg BID</title>
          <description>Fluticasone Propionate: OPN-375 186 μg BID, Delivered via exhalation delivery system</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fungal Skin Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tension Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nasal Discharge Discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vasomotor Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Disclosure agreement is described in CTA between sponsor and PI</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Carothers</name_or_title>
      <organization>Optinose</organization>
      <phone>908-432-3061</phone>
      <email>jennifer.carothers@optinose.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

